---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-022023"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2025-06-10T23:59:59+00:00"
generated_at: "2026-05-19T15:08:33.833270+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Insmed TPIP Phase 2b in PAH meets primary endpoint with 35% PVR reduction (p<0.001)

## Summary
- Placebo-adjusted PVR reduction 35% (p<0.001); 6MWD improvement 35.5 m (p=0.003); NT-proBNP reduction 60% (p<0.001).
- Once-daily TPIP well tolerated; 75% of patients titrated to max dose 640 µg; 90% completed study.
- Insmed to engage FDA for Phase 3; PH-ILD Phase 3 by end 2025; PAH Phase 3 early 2026.
- Common TEAEs: cough 40.6%, headache 31.9%, fatigue 10.1%; no deaths in study.
- 95% of completers enrolled in open-label extension (1,280 µg max dose allowed).

## SEC filing metadata
- accession: 0001140361-25-022023
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2025-06-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036125022023/0001140361-25-022023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036125022023/ef20050418_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-022023
- JSON: https://secwatch.observer/filing/0001140361-25-022023.json
- Plain text: https://secwatch.observer/filing/0001140361-25-022023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.